Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11157476 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Conditions: Hodgkin Disease;   Hodgkin Lymphoma
Interventions: Radiation: 111In-daclizumab;   Radiation: 90Y-daclizumab

Indicates status has not been verified in more than two years